-
Mashup Score: 1AUA 2023: Characteristics and Outcomes of Patients with Advanced Prostate Cancer Treated with Relugolix: A Single Center Experience - 1 year(s) ago
AUA 2023, prostate cancer, Relugolix, oral gonadotropin-releasing hormone (GnRH), HERO trial, Outcomes of Patients with Advanced Prostate Cancer Treated with Relugolix.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 3ASCO GU 2023: A Multi-Center, Prospective, Observational Study of Patients with Prostate Cancer Being Treated with Relugolix: OPTYX - 1 year(s) ago
Prostate Cancer, Relugolix, OPTYX, American Society of Clinical Oncology Genitourinary (ASCO GU), ASCO GU 2023, gonadotropin-releasing hormone (GnRH), androgen deprivation therapy (ADT), CaPSURE trial, AQUAtrial, IRONMAN trial.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
A multi-center, prospective, observational study of patients with #ProstateCancer being treated with #Relugolix - #OPTYX. Presented by @DrSpratticus @RadoncUh. @ASCO #GU23 written coverage by @rksayyid @UofT > https://t.co/5gOlBo4ash https://t.co/FcnFvUmQN9
-
-
Mashup Score: 0
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
#Relugolix is available, but additional clinical trial investigation is ongoing. Evan Yu, MD @fredhutch discusses the use of relugolix in this article on UroToday > https://t.co/xOrnNvTrfk @SeattleCCA @UW https://t.co/OpwOSchgXb
-
-
Mashup Score: 0
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
#Relugolix is available, but additional clinical trial investigation is ongoing. Evan Yu, MD @fredhutch discusses the use of relugolix in this article on UroToday > https://t.co/xOrnNvTZ4S @SeattleCCA @UW https://t.co/qhUyLU9wR1
-
-
Mashup Score: 0
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet-
#Relugolix is available, but additional clinical trial investigation is ongoing. Evan Yu, MD @fredhutch discusses the use of relugolix in this article on UroToday > https://t.co/xOrnNvTZ4S @SeattleCCA @UW https://t.co/IGxUxILGlt
-
-
Mashup Score: 0
The FDA recently announced the acceptance of a supplemental New Drug Application for relugolix 40 mg, estradiol 1 mg, and norethindrone acetate .5 mg in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
Source: Contemporary PediatricsCategories: Latest Headlines, PediatricsTweet-
The #FDA recently announced the acceptance of a supplemental New Drug Application for #relugolix 40 mg, #estradiol 1 mg, and norethindrone #acetate .5 mg in the treatment of heavy menstrual bleeding associated with #UterineFibroids in premenopausal women. https://t.co/GboMWd61XO https://t.co/ebcTvqVYrW
-
-
Mashup Score: 0EU panel backs approval of relugolix for prostate cancer - 2 year(s) ago
The approval recommendation for the GnRH receptor antagonist is based on data from the phase 3 HERO study.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
EU panel recommends approval of relugolix for prostate cancer https://t.co/h4Dlof3tyx #ProstateCancer #Relugolix #Urology #Urologist
-
-
Mashup Score: 0EU panel backs approval of relugolix for prostate cancer - 2 year(s) ago
The approval recommendation for the GnRH receptor antagonist is based on data from the phase 3 HERO study.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
EU bases recommendation of relugolix approval for prostate cancer using phase 3 HERO study https://t.co/lDVOpVYuYX #Relugolix #ProstateCancer #Urology #Urologist
-
-
Mashup Score: 0EU panel backs approval of relugolix for prostate cancer - 2 year(s) ago
The approval recommendation for the GnRH receptor antagonist is based on data from the phase 3 HERO study.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Relugolix approval backed by EU panel for advanced hormone-sensitive prostate cancer https://t.co/nTXPlhrfE4 #ProstateCancer #Relugolix #Urology #Urologist
-
-
Mashup Score: 0EU panel backs approval of relugolix for prostate cancer - 2 year(s) ago
The approval recommendation for the GnRH receptor antagonist is based on data from the phase 3 HERO study.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
EU panel supports approval of relugolix for prostate cancer https://t.co/aiSgjOkFoV #ProstateCancer #Relugolix #Urology #Urologist
-
Characteristics and outcomes of patients with advanced #ProstateCancer treated with #relugolix: a single center experience. Presentation by Parth Shah @NUFeinbergMed. #AUA23 written coverage by @rksayyid @UofT > https://t.co/RTp3g7wZcV @AmerUrological https://t.co/vLAYR2Zire